Contract between Chimerix and BARDA extended

Chimerix, Inc., announced on June 3 that it is extending its contract with Biomedical Advanced Research and Development Authority for the continued development of CMX001.

CMX001 is a potential medical treatment for smallpox. It is being developed as a treatment or preventive therapeutic for multiple viral diseases, which is based on its antiviral activity against all five families of double-stranded DNA viruses that cause disease in humans. Smallpox is included in this double-stranded DNA virus.

"CMX001 continues to show progress as a potential medical countermeasure against smallpox, including recent data generated in a highly relevant rabbitpox model," Kenneth I. Moch, president and CEO of Chimerix, said. "We look forward to continuing our work with BARDA and the FDA to advance CMX001 as a medical countermeasure for smallpox. Simultaneously, we are also continuing the development of CMX001 for the prevention, preemption or treatment of other dsDNA viruses, including herpesviruses, polyomaviruses, and adenoviruses, that cause morbidity and mortality in immunocompromised individuals."

Smallpox is declared to be eradicated in humans. Because of this, the development of CMX001 is being done under the FDA's Animal Efficacy Rule. Smallpox is still considered to be a Category A bioterror agent.

The contract extension provides $5 million in funding for over 12 months. The money will be used to conduct animal studies necessary for the approval of CMX001 by the FDA.